902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options 2

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options

Evaluation of CAR T access barriers in Washington and Alaska A single center experience prior to implementing program capacity expansion

Artificial intelligence driven GVHD scoring and response tracking Advancing FACT compliance clinical trial readiness and evidence based therapy in a transplant program

Lessons learned from the clinical trial portfolio of ixazomib in multiple myeloma A systematic review and meta analysis

Integrating bispecific antibodies into VA oncology care A multidisciplinary protocol and education model from visn 20

Cost effectiveness of frontline blinatumomab in children with standard risk B cell acute lymphoblastic leukemia in Ontario Canada

Evaluating the efficacy of montelukast in reducing the incidence and severity of monoclonal antibodies associated infusion reactions Phase II Study

Implementation and utility of measurable residual disease MRD testing for multiple myeloma patients at a VA medical center

US cost consequence and time toxicity model for advanced therapies in the treatment for Relapsed Refractory third line or later diffuse large B cell lymphoma A comparison of axicabtagene ciloleucel with bispecific antibodies

Access to diagnostics therapies and advanced care for lymphoma in Latin America A multicenter survey based study

Expanding the boundaries of CAR T cell therapy Implementation of an outpatient at home OATH model

Mortality trends in patients with co occurring hematologic malignancies and heart failure in the United States population A 25 year analysis using the CDC wonder database

Reassessing pre chemotherapy laboratory testing in R CHOP Are we doing too much

Optimizing time to IV methotrexate initiation for planned admissions to the inpatient hematology oncology service

Ensuring equitable access to bispecific antibodies in multiple myeloma Findings from the emmbrace patient and public involvement and engagement PPIE sessions

The exact system for precision clinical trial matching Case study of accuracy with follicular lymphoma trials

Clinical implications and prevalence of benign ethnic neutropenia BEN in lymphoma patients of middle eastern ethnicity

Optimizing processes for adverse event management for bispecific antibodies for diffuse large b cell lymphoma in community practice Insights from a quality improvement initiative

Understanding secondary immunodeficiency management in patients with hematological malignancies

Diverse preferences for treatment options in relapsed refractory R R follicular lymphoma FL Survey results from patients in the United States US

Patients with relapsed refractory R R diffuse large B cell lymphoma DLBCL preferred fixed duration treatments with less frequent administrations in the era of novel bispecific antibodies BsAbs

Cost effectiveness analysis of mosunetuzumab compared with novel alternative immunotherapies in patients with third line or later relapsed refractory follicular lymphoma in Japan

Increasing guideline based anti emetic prophylaxis for chemotherapy induced nausea vomiting within a quaternary pediatric hospital